460 related articles for article (PubMed ID: 33326564)
1. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.
DeRonne BM; Wong KR; Schultz E; Jones E; Krebs EE
Am J Health Syst Pharm; 2021 Feb; 78(4):354-359. PubMed ID: 33326564
[TBL] [Abstract][Full Text] [Related]
2. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
3. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
4. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
[TBL] [Abstract][Full Text] [Related]
5. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Cochran G; Bruneau J; Cox N; Gordon AJ
Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
[TBL] [Abstract][Full Text] [Related]
6. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
Smith A; Hansen J; Colvard M
J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
[TBL] [Abstract][Full Text] [Related]
7. Barriers and facilitators to implementing medications for opioid use disorder and naloxone distribution in Veterans Affairs emergency departments.
Sasson C; Dieujuste N; Klocko R; Basrai Z; Celedon M; Hsiao J; Himstreet J; Hoffman J; Pfaff C; Malmstrom R; Smith J; Holstein A; Johnson-Koenke R
Acad Emerg Med; 2023 Apr; 30(4):289-298. PubMed ID: 36757683
[TBL] [Abstract][Full Text] [Related]
8. Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities.
Hawkins EJ; Danner AN; Malte CA; Blanchard BE; Williams EC; Hagedorn HJ; Gordon AJ; Drexler K; Burden JL; Knoeppel J; Lott A; Sayre GG; Midboe AM; Saxon AJ
Addict Sci Clin Pract; 2021 Sep; 16(1):55. PubMed ID: 34488892
[TBL] [Abstract][Full Text] [Related]
9. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
[TBL] [Abstract][Full Text] [Related]
10. Increasing Access to Medications for Opioid Use Disorder and Complementary and Integrative Health Services in Primary Care.
Chang ET; Oberman RS; Cohen AN; Taylor SL; Gumm E; Mardian AS; Toy S; Revote A; Lewkowitz B; Yano EM
J Gen Intern Med; 2020 Dec; 35(Suppl 3):918-926. PubMed ID: 33145686
[TBL] [Abstract][Full Text] [Related]
11. Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations.
McLeman B; Gauthier P; Lester LS; Homsted F; Gardner V; Moore SK; Joudrey PJ; Saldana L; Cochran G; Harris JP; Hefner K; Chongsi E; Kramer K; Vena A; Ottesen RA; Gallant T; Boggis JS; Rao D; Page M; Cox N; Iandiorio M; Ambaah E; Ghitza U; Fiellin DA; Marsch LA
Addict Sci Clin Pract; 2024 Mar; 19(1):18. PubMed ID: 38500166
[TBL] [Abstract][Full Text] [Related]
12. Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study.
Miller WA; Gordon AJ; Clothier BA; Ackland PE; Bounthavong M; Garcia C; Kenny ME; Noorbaloochi S; Hagedorn HJ
Implement Res Pract; 2023; 4():26334895231199463. PubMed ID: 37790176
[TBL] [Abstract][Full Text] [Related]
13. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
[TBL] [Abstract][Full Text] [Related]
14. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
[TBL] [Abstract][Full Text] [Related]
15. Medications for opioid use disorder prescribed at hospital discharge associated with decreased opioid agonist dispensing in patients with opioid use disorder requiring critical care: A retrospective study.
Quaye A; Wampole C; Riker RR; Seder DB; Sauer WJ; Richard J; Craig W; Gagnon DJ
J Subst Use Addict Treat; 2023 Dec; 155():209176. PubMed ID: 37778703
[TBL] [Abstract][Full Text] [Related]
16. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
[TBL] [Abstract][Full Text] [Related]
17. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
[TBL] [Abstract][Full Text] [Related]
18. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
[TBL] [Abstract][Full Text] [Related]
19. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
Finlay AK; Wong JJ; Ellerbe LS; Rubinsky A; Gupta S; Bowe TR; Schmidt EM; Timko C; Burden JL; Harris AHS
J Stud Alcohol Drugs; 2018 Nov; 79(6):909-917. PubMed ID: 30573022
[TBL] [Abstract][Full Text] [Related]
20. Deploying science to change hearts and minds: Responding to the opioid crisis.
Walsh SL; Long KQX
Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
